Sintrom 1 mg

Sintrom Tablet is a product of Paladin Labs Inc

Group: Approved Anticoagulants / Vitamin K Antagonists

Name: Sintrom

Dosage: Tablet

Strength: 1 mg

Route: Oral

Pharmaceutical company : Paladin Labs Inc

You can also find other alternative products such as : Sintrom (1 mg) from Paladin Labs Inc Sintrom (4 mg) from Paladin Labs Inc

Indication: For the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.

Category:

  • 4-Hydroxycoumarins
  • Anticoagulants
  • Benzopyrans
  • Blood and Blood Forming Organs
  • Coumarins
  • Cytochrome P-450 CYP1A2 Substrates
  • Cytochrome P-450 CYP2C19 Substrates
  • Cytochrome P-450 CYP2C9 Substrates
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Substrates
  • Cytochrome P-450 Enzyme Inhibitors
  • Hematologic Agents
  • Narrow Therapeutic Index Drugs
  • Pyrans
  • Vitamin K Antagonists
  • Food Interactions; High doses of vitamin A, C, E and K (e.g. avocado, green vegetables)

    Acenocoumarol Definition:
    Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, XI and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.

    More Sintrom 1 mg

    L-CARNITINE

    Therapeutic indications


    Warfarin (Coumadin) interacts with L-CARNITINEWarfarin (Coumadin) is used to slow blood clotting..**Side Effects & Safety****Interactions?**Be cautious with this combinationAcenocoumarol (Sintrom) interacts with L-CARNITINEAcenocoumarol (Sintrom) is used to slow blood clotting..


    OSMOPREP Rx

    Therapeutic indications Constipation and bowel cleansers


    Bowel perforation..C).. Caution with drugs that prolong QT interval, affect electrolytes or renal function (eg, diuretics, ACEIs, ARBs, NSAIDs), or lower seizure threshold..


    KADCYLA Rx

    Therapeutic indications Breast cancer


    Assess LVEF prior to initiation and every 3 months during treatment; interrupt and discontinue as appropriate.. Caution with concomitant anticoagulation or antiplatelet therapy; monitor closely.. Monitor for neurotoxicity; withhold temporarily if Grade 3 or 4 peripheral neuropathy occurs..


    KADCYLA Rx

    Therapeutic indications Breast cancer


    Patients should have either: received prior therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy.. Caution with concomitant anticoagulation or antiplatelet therapy; monitor closely.. Permanently discontinue if interstitial lung disease or pneumonitis occurs..


    Effects of Sintrom 1 mg by reaction with another drug or drugs

  • Mesterolone may increase the anticoagulant activities of Acenocoumarol.
  • The serum concentration of 7-Deazaguanine can be increased when it is combined with Acenocoumarol.
  • Phenprocoumon may increase the anticoagulant activities of Acenocoumarol.
  • The risk or severity of bleeding can be increased when Tigecycline is combined with Acenocoumarol.
  • The metabolism of Acenocoumarol can be decreased when combined with Zaleplon.
  • The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Sulfametopyrazine.
  • The metabolism of Acenocoumarol can be decreased when combined with Paricalcitol.
  • Zeranol may decrease the anticoagulant activities of Acenocoumarol.
  • The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Sulfachlorpyridazine.
  • The serum concentration of Acenocoumarol can be increased when it is combined with Propafenone.
  • The risk or severity of bleeding can be increased when Tenecteplase is combined with Acenocoumarol.
  • The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Meticrane.
  • Ceftriaxone may increase the anticoagulant activities of Acenocoumarol.
  • The metabolism of Acenocoumarol can be decreased when combined with Midostaurin.
  • Nepafenac may increase the anticoagulant activities of Acenocoumarol.
  • The metabolism of Acenocoumarol can be decreased when combined with Duloxetine.
  • The metabolism of Acenocoumarol can be decreased when combined with Ezetimibe.
  • The metabolism of Acenocoumarol can be decreased when combined with Thioridazine.
  • Glipizide may increase the anticoagulant activities of Acenocoumarol.
  • The metabolism of Acenocoumarol can be decreased when combined with Simvastatin.